Interval between planning and frameless stereotactic radiotherapy for brain metastases: are our margins still accurate? by Bronnimann, Charlotte et al.
HAL Id: hal-02406540
https://hal.inria.fr/hal-02406540
Submitted on 12 Dec 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Interval between planning and frameless stereotactic
radiotherapy for brain metastases: are our margins still
accurate?
Charlotte Bronnimann, Aymeri Huchet, Julie Benech-Faure, Caroline
Dutriaux, Olivier Saut, Eivind Blais, Olivier Mollier, Renaud Trouette,
Véronique Vendrely
To cite this version:
Charlotte Bronnimann, Aymeri Huchet, Julie Benech-Faure, Caroline Dutriaux, Olivier Saut, et al..
Interval between planning and frameless stereotactic radiotherapy for brain metastases: are our mar-




 Interval between planning and frameless stereotactic radiotherapy for brain metastases: are 
our margins still accurate? 
Charlotte Bronnimann1, Aymeri Huchet2, Julie Benech-Faure2, Caroline Dutriaux1, Olivier Saut3, 
Eivind Blais2, Olivier Mollier4, Renaud Trouette2, Veronique Vendrely2-5 
Afiliations: 1 CHU-Bordeaux, Oncology department, F-33000 Bordeaux, France, 2 CHU Bordeaux, 
Radiotherapy department, F-33000 Bordeaux, France, 3 INRIA Bordeaux Sud-Ouest, 33405 Talence 
cedex, 4 CHU-Bordeaux, Neurosurgery department, F-33000 Bordeaux, France, 5 University of 
Bordeaux, INSERM U1035, F-33000 Bordeaux, France 
Corresponding Author: Dr Aymeri Huchet, Radiothérapie, Hôpital du Haut-Lévêque, Avenue de 
Magellan 33600 Pessac, France.    Tel: (+33) (0) 5.57.62.33.00, Fax: (+33) (0) 556723305, E-mail: 
aymeri.huchet@chu-bordeaux.fr 
Total number of pages: 12 
Number of tables: 2  
Number of figures: 3 
Running head: Impact of interval on treatment accuracy 
Contribution of each author: Charlotte Bronnimann and Aymeri Huchet acquired the datas, and wrote 
the manuscript, figures and tables. Julie Benech-Faure reviewed all the radiotherapy physics; Olivier 
Saut realized the statistics; Caroline Dutriaux, Eivind Blais, Olivier Mollier, Renaud Trouette, and 




Background and Purpose: Advances in intracranial stereotactic radiotherapy (SRT) have led to 
dramatically reduced planning target volume (PTV) margins. However, tumour growth between 
planning and treatment may lead to treatment failure. Our purpose was to assess the kinetics of tumour 
growth before SRT for brain metastases. 
Material and Methods: this retrospective, monocentric study included all consecutive patients (pts) 
treated for brain metastases secondary to melanoma (ML) and non-small cell lung cancer (NSCLC) 
between June 2015 and May 2016. All pts underwent diagnostic brain imaging and a radiotherapy 
planning MRI, where GTV was delineated. Linear and exponential models were used to extrapolate a 
theoretical GTV at first day of treatment, and theoretical time to outgrow the PTV margins. 
Results: Twenty-three ML and 31 NSCLC brain metastases (42 pts, 84 brain imaging scans) were 
analyzed. Comparison of GTV at diagnosis and planning showed increased tumour volume for 20 ML 
pts (96%), and 22 NSCLC pts (71%). The shortest time to outgrow a 1 mm margin was 6 days and 3 
days for ML and 14 and 8 days for NSCLC with linear and exponential models respectively.    
Conclusion: Physicians should bear in mind the interval between SRT planning and treatment. A 
mathematical model could screen rapidly progressing tumours. 
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Importance of the Study  
In a context of high precision and reduced margins, our study aims to assess the interval between 
planning and stereotactic radiotherapy of brain metastases, possibly responsible for undertreatment of 
tumours. We estimated tumour growth using linear and exponential models, in order to calculate a 
theoretical time to outgrow the PTV margins. This extrapolation has never been made. We found that 
tumour growth kinetic depended predominantly on histology and could be aggressively rapid. The 
present work underlined the necessity of personalizing treatment. Physicians should keep in mind time 







Prognosis for non-small-cell lung cancer (NSCLC) and metastatic melanoma (ML) has recently 
dramatically improved thanks to targeted therapy and to immunotherapy [1]. But, the risk of spread to 
the central nervous system remains high with occurrence of brain metastasis for 40 to 60% of patients 
(pts) with metastatic ML. [2] On the other hand, more than 20% of lung cancers are associated with 
brain metastases at cancer diagnosis. [3] Hypo-fractionated SRT is considered to be a standard 
therapeutic option for pts with 1 to 5 brain metastases. [4] SRT provides a high gradient dose between 
tumour and surrounding tissue, and reduced PTV margins are used to spare the adjacent brain tissue. 
Therefore, to accurately delineate GTV, a fusion of magnetic resonance imaging (MRI) with the 
planning Computed Tomography scan (CT scan) is recommended. However, tumour growth between 
the planning CT scan and the first fraction of SRT might be responsible for an inaccurate coverage of 
the tumour, which may lead to treatment failure. Our purpose was to assess the kinetics of tumour 
growth between diagnostic imaging and planning MRI for brain metastases secondary to ML and 
NSCLC. We also evaluated, using mathematical models, the extrapolated size of the tumour at first 
day of treatment, and consequences in terms of inaccurate coverage of the tumour possibly leading to 
treatment failure. In addition, we estimated the theoretical interval for each tumour to outgrow the 
PTV margin. 
 
Material and Methods 
Patients. This retrospective, monocentric study included all consecutive pts treated with SRT for brain 
metastases secondary to ML or NSCLC between June 2015 and May 2016 at Bordeaux University 
Hospital, France. The eligibility criteria were: age > 18 years, histologically proved ML or NSCLC, 
and brain imaging data finding 1 to 5 brain metastases. Only non-resected metastases were analyzed. 
Pts with previous craniotomy were eligible if they had a new brain metastasis. Diagnosis of brain 
metastases was done on CT or MRI imaging and reviewed for confirmation by a multidisciplinary 
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board, including radiation oncologists, medical oncologists, neurosurgeons, and radiologists. Imaging 
consisted of cerebral CT scan or MRI with a contrast enhancement sequence. Pts with only one 
imaging scan available or with intra-tumoural bleeding were excluded. The institutional review board 
approved the study and the need for written informed consent was waived. 
Radiation therapy. For SRT planning, all pts underwent a high-resolution, 3-dimensional T1-
weighted gadolinium-enhanced MRI sequence, reconstructed every 1.0 mm. A CT scan was carried 
out for radiation therapy planning using a slice reconstruction every 1.0 mm and a field of 35 cm. A 
thermoplastic mask was used for immobilization. The Eclipse treatment planning system (Varian 
Medical Systems, CA version 13.5) was used to co-register the MRI and CT scan and to segment 
structures: optics, brainstem, spinal cord, retinas, brain, pituitary gland, GTV and PTV. Margins from 
GTV to PTV used in our institution were 2 mm. Dose was prescribed in order to ensure a minimal 
coverage of 90% of the PTV before validation of the treatment planning. SRT doses were 1 fraction of 
20 Gy, 3 fractions of 9, 10 or 11 Gy or 5 fractions of 5 Gy depending on tumour size. Treatment was 
delivered using 6MV photons, by Elekta T.M. Versa HD T.M. associated with Fraxio T.M. system for 
stereotaxy. Exatrac T.M.  system was used to adapt setting of the patient using a 6D rotation table for 
treatment.    
Assessment. Baseline patient characteristics included KPS, RPA status, steroid treatment, number and 
location of brain metastases. Brain imaging consisted of MRI with gadolinium-enhanced sequences, or 
CT scan with intravenous contrast. Time at brain metastasis diagnosis, radiotherapy planning imaging 
and first day of treatment were recorded. The follow-up examinations consisted of an MRI scan every 
3 months for 1 year and every 6 months thereafter. The primary endpoint was to assess the kinetics of 
tumour growth of brain metastases between diagnostic imaging and radiotherapy planning imaging, 
and to extrapolate the theoretical tumour volume at the time of SRT. Both types of imaging were 
implemented using the Eclipse system version 13.5. GTV was delineated on the basis of contrast 
enhancement by a radiation oncologist experienced in the treatment of brain metastases by SRT. 
GTV1, GTV2 and GTV3 corresponded respectively to GTV at diagnosis, on the planning imaging and 
the estimated volume at first day of treatment with linear extrapolation or exponential extrapolation. 
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The secondary endpoints were to assess tumour control and radiation induced toxicities during follow-
up. Toxicity was scored according to the common terminology criteria for adverse events (CTACAE 
v4.0). A progressive disease was defined as a radiological progression without radio-necrosis criteria 
in accordance with the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) 
working group. Radio-necrosis was diagnosed according to imaging features, such as increased 
contrast enhancement, non-progression of lesion over 4 months and reduced perfusion on dynamic 
MRI sequences.  
 
Statistical analysis. Linear extrapolation and exponential extrapolation were used to estimate the t 
minimum theoretical time allowing tumour diameter to increase by more than 4 mm (T-4mm) and 
more than 2 mm (T-2mm) from radiotherapy planning imaging. Univariate analysis was carried out on 
patient characteristics to analyze the predictive parameters of radio-necrosis 
 
Results 
Patients. Out of 103 pts treated for brain metastases by SRT between June 2015 and May 2016, 21 
were treated for ML and 21 for NSCLC. Two pts were excluded because of lack of imaging data. The 
median age was 71.4 years old for ML pts (range 25-92) and 67.7 years old for NSCLC pts (range 48-
82). Only 1 patient with ML was RPA class 1. Other patients were RPA class 2 for 17 ML pts (81%) 
and 16 NSCLC pts (76%) and class 3 for 3 ML pts (14%) and 5 NSCLC pts (24%). A systemic 
treatment was given at diagnosis for 14 ML pts (67 %) and 7 NSCLC pts (33%), including 
immunotherapy for 6 ML pts, targeted therapy for 5 ML pts and 1 NSCLC pt and conventional 
chemotherapy for 3 ML pts and 6 NSCLC pts. Brain metastases in ML or NSCLC pts were 
synchronous to ML or NSCLC diagnosis respectively in 3 and 11 cases, or metachrone in 18 and 10 
cases, with a median time of 4.8 years [1- 40 years] and 2.1 [1 -9.5 years] for ML and NSCLC 
respectively (Table 1).  





Metastases. A total of 23 ML and 31 NSCLC metastases were analyzed from 42 pts. One NSCLC 
patient with 1 metastasis was excluded due to tumour bleeding. Location was supra-tentorial in 38 
cases, cerebellar in 3 cases and mesencephalic in 1 case. Six pts had already received SRT for previous 
other brain metastases. One patient received previous whole-brain radiotherapy (30 Gy/10 fractions). 
All metastases analyzed had not been previously irradiated. Radiotherapy was delivered according to a 
monofraction scheme for 5 ML and 3 NSCLC metastases, 3-fraction scheme for 15 ML and 25 
NSCLC metastases, or 5-fraction scheme for 3 ML and 2 NSCLC metastases (Table 1).  
Assessment. Eighty-four brain imaging scans (67 MRI, 17 CT-scan) were analyzed. Comparison of 
imaging between diagnosis and radiotherapy planning showed increased tumour volume for 22 ML 
and 22 NSCLC metastases; stability for 1 ML and 7 NSCLC metastases, bleeding inside one NSCLC 
metastasis (excluded) and 1 metastasis volume decrease (Figure 1).   
Median time between brain imaging at diagnosis and radiotherapy planning imaging was 24 days for 
ML and 29 days for NSCLC. Median time between radiotherapy planning imaging and first day of 
radiotherapy was 19 days for ML and for NSCLC. Median time between brain imaging at diagnosis 
and first day of treatment was similar for ML and NSCLC (Table 2). For each patient, tumour growth 
was calculated between diagnosis and treatment planning, and extrapolated between planning and SRT 
(Figure 2). Median GTV1 was 0.5 cm3 for ML and 0.4 cm3 for NSCLC; median GTV2 was 1.5 cm3 
for ML and 0.8 cm3 for NSCLC. GTV3 at first day of treatment for ML were significantly increased 
than NSCLC with linear and exponential model (respectively 2.1 cm3 versus 1.2 cm3 and 4.3cm3 
versus 1.6cm3, p=0.05) (Figure 3).  
The shorter T-4mm was 15 days or 6 days for ML and 32 or 15 days for NSCLC with respectively the 
linear or exponential models. Real time from planning imaging to first day of treatment was then 
compared to the theoretical time T4mm. Linear and exponential models showed respectively 2 ML 
Mis en forme : Anglais (E.U.)
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and no NSCLC and 11 ML and 1 NSCLC expected to outgrow the PTV margins on the first day of 
treatment. These metastases were potentially undertreated. 
The shortest T-2mm was 6 days or 3 days for ML and 14 or 8 days for NSCLC with respectively the 
linear or exponential models. Twelve ML and 3 NSCLC were expected to outgrow the PTV margins 
during the first day of treatment according to the linear model whereas the exponential model 
predicted the same concern for 14 ML and 7 NSCLC. 
Follow-up. Median follow-up was 12 and 17 months for ML and NSCLC pts respectively. Brain 
metastases were controlled at the end of the follow-up for all except two ML cases. One brain 
metastasis had a tumour bleeding 16 months after SRT. Four pts died from extracranial cancer 
progression (ML: 2 pts, NSCLC: 2 pts), and three ML pts died from new brain metastases. At 3 
months, out of 39 patients alive, 11 had at least one new brain metastasis (ML: 5 pts, NSCLC: 6 pts). 
Acute toxicity included only one Grade 1 asthenia during treatment. Radio-necrosis was observed for 
8/21 ML (36%) and 8/22 (36%) NSCLC, asymptomatic for 15 metastases and symptomatic for only 
one pt. Out of 8 (6 ML, 2 NSCLC) pts with steroids prescribed due to brain metastasis neurological 
symptoms, 3 (1 ML, 2 NSCLC) experienced radio-necrosis. 5 additional pts required steroids after 
radiation for symptomatic radio-necrosis. No effect of steroids on the tumor volume was observed. 
None of the patients with radio-necrosis received bevacizumab. No predictive parameter for radio-
necrosis was found in univariate analysis.  
 
Discussion 
SRT is now considered to be the standard treatment for 1-3 non-resectable brain metastases 
and has dramatically changed the management of brain metastases. [5] Major advances in imaging and 
radiotherapy techniques enable high doses to be delivered to focal cancers, with reduced margins. [6] 
Current trends continue to focus on improvement of SRT accuracy. Nevertheless, concerns may be 
raised about potential risks of treatment failure due to tumour growth during the interval between 
treatment planning and initiation of SRT. This is the reason why we assessed tumour growth before 
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treatment of ML and NSCLC brain metastases and the risk of inaccurate coverage of the tumour 
relating to time before SRT.  
Radio-necrosis was observed in 8 of 21 irradiated MLs, symptomatic only in one case. 
Incidence of radio-necrosis is estimated from 10 to 25% [9, 10]. Using imaging-based diagnosis, 
Minniti et al. reported a 24% incidence of RN (14% symptomatic, 10% asymptomatic) [9]. Renal 
carcinoma, lung adenocarcinoma (ALK rearrangement specifically), HER2-amplied breast cancer, and 
BRAF V600 wild-type melanoma are suggested to present a higher risk of radio-necrosis [10]. These 
considerations could explain the present high rate of radio-necrosis. No predictive parameter was 
found in our study. [9] Our inclusion criteria excluded 2 rather specific situations of ML: bleeding 
before treatment that lead to cancellation of SRT and occurence of new ML or NSCLC between 
diagnosis and radiotherapy planning MRI. Indeed, delineation of bleeding tumour volume remained 
controversial and tumour evolution could not be predicted with linear or extrapolation model for this 
type of metastasis. Bleeding metastases are currently managed by neurosurgeons.  
Time from diagnosis to planning may result from the requirements of systemic treatments. 
This interval may also be explained by the poor availability of the SRT technique in some centres, and 
to the period before referring the patient to a stereotactic radiation unit. To our knowledge, the interval 
between diagnosis and initiation of SRT has not yet been assessed. In addition, the interval between 
radiotherapy planning and first day of treatment may differ between centres due to specific local 
organization. [7]  
 Two series reported the interval between treatment planning and radiosurgery for brain 
metastases. Seymour reported 82 pts with heterogeneous brain metastases. Time from radiation 
oncologist consultation to radiotherapy planning MRI was 28 days. Time from planning MRI to first 
day of treatment was 11 days. In most of the cases, diagnosis of brain metastases was established 
before the radiation oncologist consultation. Hence, our delays were roughly similar. In previous 
publications, local failure-free progression dramatically decreased when time from planning MRI to 
treatment was less than 14 days. [7] Garcia et al. reported a second series of 256 pts treated for brain 
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metastases with fixed frame radiosurgery (SRS). The mean time between diagnosis of metastases and 
MRI on day of treatment was 25 days. In this technique of fixed frame SRS, the treatment planning 
MRI was carried out the same day as the treatment. Growth of brain metastases was observed in 30% 
of patients, particularly for melanoma. However, local failure-free progression was not compromised 
when growth of brain metastases was observed before treatment planning. [8]  
Our study showed a tumour progression for 82 % of brain metastases. As expected, time to 
outgrow a 1mm PTV margin (=T2mm) was short and clinicians should be careful with intervals when 
using 1mm margin from GTV to PTV. The choice of extrapolation model may lead to over or under 
estimation of the size of the tumour on the first day of treatment. No patient underwent brain imaging 
on the first day of treatment in order to validate our models. A prospective study with imaging on the 
first day of treatment would help statisticians and physicians to identify the best model for prediction 
of metastasis evolution. Interestingly, among the 2 patients who experienced a local failure, one was 
considered at risk of undertreatment according to our models. Time from planning imaging to 
treatment may lead to underestimation of the real GTV.[10] The present series highlights the need to 
reconsider our current management. To overcome this interval, one option could be to adapt the 
margin to the time to treatment. However, this may be considered non-ethical. [9] The other option is 
to reconsider the planning of the radiotherapy process.  
Interestingly, we found a difference in tumour growth between ML and NSCLCC metastases. 
Initial median volumes were similar (0.50 and 0.45 cm3 respectively for ML and NSCLC), whereas 
median GTV2 was higher in melanoma (1.5 cm3) than in lung cancer (0.8 cm3). The slower tumour 
growth in lung cancer explained the 1 NSCLC with a long interval between diagnosis and treatment 
planning because of diagnostic doubt. This study highlighted that the heterogeneity between cancer 
types needs to be considered in brain metastases. Other studies will be necessary to identify rapid 
progression brain metastases that should be the treated earlier with SRT or surgery. On the other hand, 





Conclusion: Physicians should bear in mind the interval between SRT planning and treatment, 
especially using a 1mm margin. Growth of brain metastases is highly heterogenic between cancer 
types. A mathematical model could help to screen rapidly progressive tumours, in order to 
individualize treatment.  
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Captions for all illustrations 
Figure 1. Brain metastasis evolution from diagnostic imaging (A, C, E, G) to treatment planning 
imaging (B, D, F, H). 
Figure 2. Evolution of brain metastases in ML and NSCLC. J0 corresponds to planning cerebral 
imaging, with corresponding GTV (GTV2) on Y axis.  Negative part was time at diagnostic imaging 
for each brain metastasis with assessment of corresponding GTV (GTV1) on Y axis. Positive part was 
time/interval to SRT, associated for each metastasis to the predictive GTV (GTV3) at time to 
treatment (with linear extrapolation).  
Figure 3. Box plots illustrative of GTV evolution at diagnosis (GTV1), at treatment planning (GTV2) 
and predictive of the first day of radiation (GTV3) for ML and NSCLC brain metastases.   
 
Table 1. Characteristics of patients treated with stereotactic radiation for brain metastases secondary to 
ML or NSCLC. 
 
Table 2. Characteristics of ML and NSCLC metastases time to treatment and evolution of tumour 
volume. 
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